Nasdaq stocks posting largest percentage increases

[AP] – A look at the 10 biggest percentage gainers on Nasdaq at the close of trading: Tonix Pharma rose 26.5 percent to $7.40. Trillium Therapeutic rose 16.4 percent to $11.12. Ebix Inc. rose 14.3 per…Read More »

NW BIO'S PHASE III TRIAL OF DCVAX®-L FOR GBM BRAIN CANCER APPROVED TO PROCEED IN CANADA AND UNDER WAY AT TWO SITES

[PR Newswire] – BETHESDA, Md., Feb. 19, 2015 /PRNewswire/ — Northwest Biotherapeutics (NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor c…Read More »

Puts rise in Northwest Biotherapeutics

NORTHWEST BIOTHERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure

NW Bio To Present At 17th Annual BIO CEO & Investor Conference

[PR Newswire] – BETHESDA, Md., Feb. 6, 2015 /PRNewswire/ — Northwest Biotherapeutics, Inc. (NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable…Read More »
Northwest Biotherapeutics (NASDAQ: NWBO) is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs.

Company Information

Company Website: http://www.nwbio.com/
Company Headquarters

4800 Montgomery Lane, Suite 800
Bethesda, MD 20814
Phone: (240) 497-9024

Media Contact

Les Goldman
Phone: (202) 841-7909
lgoldman@nwbio.com

Farrell Kramer
(212) 710-9685
farrell.kramer@mbsvalue.com

Investor Relations Contact

Les Goldman
Phone: (202) 841-7909
lgoldman@nwbio.com

Lisa Sher
(212) 661-2220
lisa.sher@mbsvalue.com

Forward Looking Statements

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “believe,” “intend,” “design,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the use of proceeds; the exercise of the Overallotment Right and the satisfaction of customary closing conditions for such exercise; the Company’s ability to raise additional capital, risks related to the Company’s ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company’s products will demonstrate safety and efficacy, risks related to the Company’s and Cognate’s abilities to carry out the intended manufacturing expansions contemplated in the Cognate Agreements, risks related to the Company’s ability to carry out the Hospital Exemption program and risks related to possible reimbursement and pricing. Additional information on these and other factors, including Risk Factors, which could affect the Company’s results, is included in its Securities and Exchange Commission (“SEC”) filings. Finally, there may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

This Blog is official and sanctioned by Northwest Biotherapeutics | See Disclaimer | See Privacy Policy

Get Northwest Biotherapeutics Blog Post Alerts